Post-earnings recap
Reported
Thu, May 30, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ascendis Pharma reported an EPS of -$1.38, but did not provide revenue figures or guidance. Despite the miss on EPS, the stock saw a slight increase of 0.43%, indicating that investors may have reacted positively to other aspects of the company's performance or outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.38 | N/A | — |
| Revenue | N/A | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.